UPDATE 1-BioMarin autoimmune disease drug gets orphan status

* Sees to meet FDA in 2010 to determine regulatory path

* Shares up 2 pct

Nov 30 (Reuters) - BioMarin Pharmaceutical Inc (BMRN.O) said its experimental treatment for a rare autoimmune disease received orphan drug status from the U.S. Food and Drug Administration, sending its shares up 2 percent.

Last month, BioMarin had acquired Huxley Pharmaceuticals Inc, along with the rights to a proprietary form of 3,4-diaminopyridine, amifampridine phosphate, an experimental treatment for Lambert Eaton Myasthenic Syndrome (LEMS).

LEMS is a rare autoimmune disease with the symptoms of muscle weakness and also often associated with small cell lung cancer.

The treatment has already received orphan drug designation in the European Union.

"We look forward to meeting with the FDA in early 2010 to determine the necessary regulatory path for amifampridine phosphate in the U.S," Chief Executive Officer Jean-Jacques Bienaime said in a statement.

Shares of the company rose 2 percent to $16.84, before paring some gains to trade up 5 cents at $16.51 Monday morning on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Aradhana Aravindan) ((anuradha.ramanathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: anuradha.ramanathan.reuters.com@reuters.net))